Farmaceutico inglese

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
23.07.2008 - MILANO (Finanza.com)
Il gruppo farmaceutico inglese GlaxoSmithKline mostra una trimestrale in salute. Il secondo trimestre si è chiuso con un utile netto in rialzo del 13% a 1,446 miliardi di sterline, con un utile per azione di 27,2 pence contro i 24 pence del corrispondente periodo del 2007. Il fatturato è salito del 4% a 5,87 miliardi di sterline.

:cool:
 

Lupak

Nuovo Utente
Registrato
25/11/06
Messaggi
16.965
Punti reazioni
964
Stavo seguendo anche io, desideroso di entrare anche nel settore chimico-farmaceutico. Purtroppo non so valutare i multipli del settore ed il P/E a 14 non mi sembrava molto basso.
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Stavo seguendo anche io, desideroso di entrare anche nel settore chimico-farmaceutico. Purtroppo non so valutare i multipli del settore ed il P/E a 14 non mi sembrava molto basso.

Certo, ma a mio giudizio, Glaxosmithkline è un gruppo internazionale farmaceutico che, assieme a Sanofi-Aventis, Pfizer e Merck & Co, non può mancare in un portafoglio ben diversificato nel settore farma... :cool:

I dividendi sono trimestrali (in alternativa al reinvestimento in azioni...) e attualmente sommano a circa 55 pence... (4,5%) OK!
 
Ultima modifica:

asqueldaz

Nuovo Utente
Sospeso dallo Staff
Registrato
19/2/08
Messaggi
20.659
Punti reazioni
255
Tue Nov 16, 2010 7:48pm GMT

ADELPHI, Maryland - Advisers are considering whether to recommend approval of a highly anticipated lupus treatment from Human Genome Sciences Inc amid concerns the drug might increase suicides or carry other serious risks.

Benlysta could be the first medicine in a half-century to win approval for fighting the debilitating and potentially fatal autoimmune disease. Annual global sales are forecast at $2.2 billion by 2014, according to Thomson Reuters.

That would transform unprofitable biotech Human Genome into an industry star.

The company would split Benlysta profits with partner GlaxoSmithKline Plc.

A Food and Drug Administration advisory panel, set to vote later on Tuesday, heard pitches from Human Genome and patients who pushed for the medicine's approval. But FDA reviewers questioned how much benefit the drug offered and noted potential risks.

Human Genome argued the intravenous drug was an important advance for fighting lupus, a disease that causes the immune system to attack the body's own tissue and organs. That can lead to arthritis, kidney damage, chest pain, fatigue, skin rash and other problems. Organ damage can be fatal, and current treatments have severe side effects.

Lupus patients have "persevered through a decade of failed trials," said Dr. Michelle Petri, a rheumatologist at Johns Hopkins University and consultant to Human Genome. Benlysta offers "compelling efficacy" with a "favorable safety profile," she told the panel.

Forty-six-year-old Donna Flenory said lupus caused severe fatigue and joint pain that forced her to give up her career as an occupational therapist. High doses of steroids improved her symptoms for a time but repeated flare-ups sent her to the hospital every year, usually in the autumn.

After joining a study of Benlysta, "when fall rolled around I was no longer sick. I had a life again," she told the panel, adding "please realize we as patients need something."

FDA reviewers, however, suggested Benlysta might have only a modest effect on lupus symptoms and might raise the risk of death, infection, or psychiatric problems including suicide. Two patients treated with Benlysta during clinical trials killed themselves and there were no suicides with a placebo.

ANALYSTS PREDICT APPROVAL

Industry analysts said ahead of the meeting that they expected the advisory panel to endorse the drug and the FDA to ultimately approve it for sale. Many said lupus patients already faced serious health problems, and there was no clear evidence Benlysta contributed to deaths or suicides.

...


U.S. advisers back Human Genome lupus drug | Reuters
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Tue Nov 16, 2010 7:48pm GMT

ADELPHI, Maryland - Advisers are considering whether to recommend approval of a highly anticipated lupus treatment from Human Genome Sciences Inc amid concerns the drug might increase suicides or carry other serious risks.

Benlysta could be the first medicine in a half-century to win approval for fighting the debilitating and potentially fatal autoimmune disease. Annual global sales are forecast at $2.2 billion by 2014, according to Thomson Reuters.

That would transform unprofitable biotech Human Genome into an industry star.

The company would split Benlysta profits with partner GlaxoSmithKline Plc.

A Food and Drug Administration advisory panel, set to vote later on Tuesday, heard pitches from Human Genome and patients who pushed for the medicine's approval. But FDA reviewers questioned how much benefit the drug offered and noted potential risks.

Human Genome argued the intravenous drug was an important advance for fighting lupus, a disease that causes the immune system to attack the body's own tissue and organs. That can lead to arthritis, kidney damage, chest pain, fatigue, skin rash and other problems. Organ damage can be fatal, and current treatments have severe side effects.

Lupus patients have "persevered through a decade of failed trials," said Dr. Michelle Petri, a rheumatologist at Johns Hopkins University and consultant to Human Genome. Benlysta offers "compelling efficacy" with a "favorable safety profile," she told the panel.

Forty-six-year-old Donna Flenory said lupus caused severe fatigue and joint pain that forced her to give up her career as an occupational therapist. High doses of steroids improved her symptoms for a time but repeated flare-ups sent her to the hospital every year, usually in the autumn.

After joining a study of Benlysta, "when fall rolled around I was no longer sick. I had a life again," she told the panel, adding "please realize we as patients need something."

FDA reviewers, however, suggested Benlysta might have only a modest effect on lupus symptoms and might raise the risk of death, infection, or psychiatric problems including suicide. Two patients treated with Benlysta during clinical trials killed themselves and there were no suicides with a placebo.

ANALYSTS PREDICT APPROVAL

Industry analysts said ahead of the meeting that they expected the advisory panel to endorse the drug and the FDA to ultimately approve it for sale. Many said lupus patients already faced serious health problems, and there was no clear evidence Benlysta contributed to deaths or suicides.

...


U.S. advisers back Human Genome lupus drug | Reuters

:rolleyes:
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Certo, ma a mio giudizio, Glaxosmithkline è un gruppo internazionale farmaceutico che, assieme a Sanofi-Aventis, Pfizer e Merck & Co, non può mancare in un portafoglio ben diversificato nel settore farma... :cool:

I dividendi sono trimestrali (in alternativa al reinvestimento in azioni...) e attualmente sommano a circa 55 pence... (4,5%) OK!

Confermo tutto il mio vecchio post e ... preciso che ora il dividendo totale annuale di Glaxosmithkline è salito a 65 pence ... ! ;)
 
Ultima modifica:

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
03.02.2011 - MILANO (Finanza.com)

Trimestrale debole per GlaxoSmithKline.
Il gruppo farmaceutico inglese ha chiuso il quarto trimestre del 2010 con un rosso di 690 milioni di sterline da un utile di 1,63 miliardi di sterline dello stesso periodo del 2009.
Il gruppo ha deciso di alzare il dividendo annuale a 65 pence.
La società ha anche annunciato un piano di buy back di 1-2 miliardi di sterline da attuare nel corso del 2011.


Le perdite del Q4 2010 sono dovute a costi straordinari di ristrutturazione.
Titolo sugli scudi a Londra ...
:cool:
 
Ultima modifica:

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Thursday, 3rd February 2011, London, UK

Unaudited Preliminary Results Announcement for the year ended 31st December 2010

Strategic progress drives positive underlying sales growth* increasing pipeline potential and improved cash generation.

Increased dividend and new long-term share buy-back programme enhance returns to shareholders.


:cool:

Prox dividendo trimestrale di Aprile 2011 fissato a 19 pence ... ! ;)
 
Ultima modifica:

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Titolo sempre sugli scudi a Londra ... ! ;)
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Titolo attorno alle 12 £ ... :cool:
 

Paola

Paola 3.0
Registrato
23/1/00
Messaggi
26.510
Punti reazioni
643
nn amo particolarmente i farma.....
 

Allegati

  • stxx.GIF
    stxx.GIF
    57,2 KB · Visite: 95

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
nn amo particolarmente i farma.....

Per la verità, non investo nel settore pharma per aspettative di particolari performances ... Tuttavia, rispetto al passato, i titoli farmaceutici europei ed USA sono ancora abbastanza cheap, inoltre continuano a distribuire dividendi molto interessanti ... ;)

Insomma, una buona diversificazione strategica (medio-lungo periodo) del portafoglio deve prevedere una quota di investimento nel settore pharma ... :cool:
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Nella fase di minimo odierno relativo, incremento della posizione GlaxoSmithKline nel portafoglio strategico (medio-lungo periodo) ... ! :cool:
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
In data odierna (07.04.2011) dividendo di 0,19 GBP in fase di pagamento ... :cool:
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Titolo in grande spolvero ... ! ;)


PS
Coniglio tigrotto, come vedi anche le crescenti plusvalenze comprano pane ...
:yes:
 
Ultima modifica:

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research
Issued: Thursday 12 May 2011, London UK

GlaxoSmithKline (GSK), The University of Manchester, and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research (MCCIR), a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out w ith an initial investment of £5M from each partner over a three year period.

The collaboration between two UK-based pharmaceutical companies, GSK and AstraZeneca, and The University of Manchester, a premier research-led institution, will bring together scientists from both the pharmaceutical industry and academia to work collaboratively on inflammation research and translational medicine.

Scientists will be recruited for new positions to direct the research in line with strategic priorities set jointly by GSK, AstraZeneca and The University of Manchester, with the ultimate goal of translating findings into new and improved treatments. Such advances could potentially benefit the millions of people worldwide affected by diseases associated with chronic inflammation, including asthma, chronic obstructive pulmonary disease, rheumatoid arthritis and inflammatory bowel disease.

Dave Allen, Senior Vice-President of Respiratory Research at GSK, said: “The translation of basic research discoveries into new medicines is challenging, but we believe we improve our chances of success through collaborative science. The MCCIR will embody this approach, and I am delighted that GSK has been able to contribute to its development.”

Dr Menelas Pangalos, Executive Vice-President Innovative Medicines at AstraZeneca, said: “Inflammatory processes underpin many of our priority areas of research and this is a ground-breaking collaboration. The creation of the new centre is indicative of a new era of pre-competitive sharing within the pharmaceutical sector and with academic scientists, to bring our learning together to ensure the faster delivery of effective medicines to patients.”

The MCCIR will be formally opened later this year at The University of Manchester and represents a new and truly innovative vehicle to support collaborative research in the UK.

Professor Ian Jacobs, Vice-President of The University of Manchester and Dean of the Faculty of Medical and Human Sciences, commented: “The University of Manchester welcomes greatly this opportunity to ensure that some of its fundamental biomedical research will become more closely aligned with the need to develop new therapies for inflammatory diseases. This collaboration builds on the mutual understanding developed between the University and both GSK and AstraZeneca over recent years, and will bring together expertise in biomedical research from the University with the resources and drug discovery expertise from GSK and AstraZeneca to create true partnership and synergy. It firmly establishes the UK and The University of Manchester at the forefront of innovative and enterprising research into inflammatory disease.”

Minister for Universities and Science, David Willetts, said: "The announcement made today by The University of Manchester, GlaxoSmithKline and AstraZeneca is a fantastic example of partnership working and its potential to translate cutting-edge science into health and commercial benefits. It is a clear vote of confidence in the UK's world-class academic research base by our leading pharmaceutical companies and is an exciting development."

NOTES TO EDITORS:

Inflammatory diseases affect millions of people worldwide, leading to pain, disability and, in some cases, premature death. Inflammation is a process by which the body combats infection or trauma and heals itself, but in some diseases this normally beneficial mechanism is present chronically leading to cellular damage, tissue destruction and a range of painful symptoms throughout the body, including joints, internal organs, skin and connective tissue. Further understanding of the mechanisms and cell types governing inflammation, repair and resolution will allow us to develop new therapies for diseases such as asthma, rheumatoid arthritis, vasculitis, inflammatory bowel disease and many other painful chronic conditions.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit GlaxoSmithKline - do more, feel better, live longer

The University of Manchester is Britain’s most popular university and was ranked third, behind only Oxford and Cambridge, for “Research Power” (Quality and Volume) in the recent Research Assessment Exercise 2008. Its external research income is £263 million.

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: AstraZeneca - a global research-based biopharmaceutical company

:cool:
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
GlaxoSmithkline ... dvd a go-go e quotazioni in uptrend ... ! :)

Insomma, un "pharmapetroleum" ... :D
 

Allegati

  • 4ed64c88a352a5a3c8344ca6243451a4.jpg
    4ed64c88a352a5a3c8344ca6243451a4.jpg
    15,8 KB · Visite: 207

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.471
Punti reazioni
1.095
Dividendo trimestrale GlaxoSmithkline in carniere ... ! :cool:
 

Allegati

  • logo-gsk.gif
    logo-gsk.gif
    3,9 KB · Visite: 166